Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Bioavailability of CKD-337 in Healthy Male Subjects
NCT03382756Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-337 in dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Atorvastatin at 48 hours, Maximum Plasma Concentration (Cmax) of Atorvastatin at 48 hours and 2 more. Started Oct 2017; status: completed.
02
Drugs
CKD-337
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03382756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382756.